Best Imaging for Neuroblastoma
The optimal imaging approach for neuroblastoma requires a combination of cross-sectional imaging (MRI or CT with contrast) for anatomic evaluation PLUS 123I-MIBG scintigraphy with SPECT/CT for metastatic disease detection. 1
Primary Imaging Recommendations
For Initial Evaluation and Staging
Cross-sectional imaging is mandatory:
- MRI with/without contrast OR CT with contrast to evaluate soft tissue disease and assess Image-Defined Risk Factors (IDRFs) for INRG staging 1
- MRI of the spine with/without contrast specifically when paraspinal disease is present or if nerve root/spinal cord involvement is suspected 1
- MRI brain with/without contrast OR CT skull/orbits with contrast only if neurologic symptoms are present 1
Functional imaging for metastatic disease:
- 123I-MIBG imaging is the cornerstone for detecting metastatic disease due to high specificity and sensitivity (positive in up to 90% of neuroblastomas) 1
- Add SPECT or SPECT/CT at sites of known/suspected disease when available to improve sensitivity and anatomic localization 1
When MIBG Fails
18F-FDG-PET imaging should be obtained when:
- 123I-MIBG shows no avidity (occurs in ~10% of cases) 1, 2
- Mixed-avidity disease is suspected 1
- Exception: Patients <6 months with L1 adrenal tumors ≤3.1 cm (solid) or ≤5 cm (if ≥25% cystic) 1
FDG-PET/CT or PET/MRI can also serve as:
- Alternative or supplemental tools when 123I-MIBG and anatomic imaging don't correlate 1
Emerging Evidence: Advanced PET Tracers
While the NCCN guidelines establish 123I-MIBG as standard, emerging evidence from 2024 demonstrates that catecholaminergic PET tracers show superior diagnostic performance 2:
Key advantages of PET tracers (18F-FDOPA, 18F-MFBG, 68Ga-DOTA-peptides):
- Detect significantly more lesions than MIBG scintigraphy (7 out of 10 studies showed superiority on lesion-based analysis) 2
- 18F-FDOPA PET/CT exhibited the best overall diagnostic performance with sensitivity of 94% and highest superiority index 3
- Faster acquisition (single-day, ~15-20 minutes vs. multi-day MIBG protocol) 2
- Superior spatial resolution with less background noise 2
- Less sedation required in young children 2
- Can change clinical management in up to 32% of patients 2
However, these advanced PET tracers are not yet widely incorporated into standard protocols despite their apparent superiority 2
Practical Algorithm
Step 1: Obtain cross-sectional imaging (MRI preferred for paraspinal tumors; CT acceptable otherwise)
Step 2: Perform 123I-MIBG scintigraphy with SPECT/CT for metastatic evaluation
Step 3: If MIBG is negative or shows mixed avidity AND patient is ≥6 months OR has higher-risk features → obtain 18F-FDG-PET
Step 4: Consider advanced PET tracers (18F-FDOPA, 18F-MFBG, 68Ga-DOTA-peptides) if available, particularly for:
- Restaging after therapy
- Suspected relapse requiring high sensitivity
- MIBG-negative disease
- Treatment planning for targeted therapies
Critical Pitfalls to Avoid
Do not rely solely on anatomic imaging (CT/MRI): Both perform poorly for detecting stage 4 disease when used alone (CT sensitivity only 43%) 4. MRI alone had 83% sensitivity but still requires functional imaging for comprehensive staging 4.
Do not delay emergent therapy for imaging: If emergent treatment is needed, initiate it immediately but obtain 123I-MIBG or FDG-PET as soon as possible afterward, as staging must be completed before treatment when feasible 1
Do not assume all neuroblastomas are MIBG-avid: Approximately 10% show absent or low MIBG uptake, necessitating alternative imaging 2, 5
Do not use outdated response criteria: Current standards use RECIST criteria for soft tissue measurement (single longest dimension), not tumor volume 1
Scoring and Response Assessment
Use modified Curie score (North America) or SIOPEN score (Europe) for semi-quantitative interpretation of 123I-MIBG uptake 1. These validated scoring systems are essential for standardized response assessment and have prognostic implications.